fashion -WSS

fashion

author：knowledge 2025-09-30 15:16:53 - browse：229

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： With clinical trial data readouts, here's how to spot spin

WSS

Humana cuts profit projections as Medicare Advantage costs soar

Organ aging and disease risk measured by new blood test

The surgeon had a dilemma only a Nazi medical text could resolve

Takeda, Janssen join wearable maker to measure scratching

Francis Collins on trust in science and how Covid communications failed

The tragedy of Johnson & Johnson’s Covid vaccine

focus

fashion

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

How to pay for weight loss drugs and save Medicare

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How to pay for weight loss drugs and save Medicare

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Wildfire smoke exposes gaps in outdoor worker protections

CDC director unscathed in first congressional testimony

New air purifier tech could be key to improving indoor air quality

What don’t we know about an Alzheimer’s drug side effect?

hotspot

Flagship Pioneering launches a new biotech in two countries

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Takeda, Janssen join wearable maker to measure scratching

Pediatric cancer treatments threatened by a new FDA policy

30 years of 'Listening to Prozac'

explore

hotspot

leisure time

knowledge